After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results